AU2016364976B2 - Solid dispersions comprising a sGC stimulator - Google Patents

Solid dispersions comprising a sGC stimulator Download PDF

Info

Publication number
AU2016364976B2
AU2016364976B2 AU2016364976A AU2016364976A AU2016364976B2 AU 2016364976 B2 AU2016364976 B2 AU 2016364976B2 AU 2016364976 A AU2016364976 A AU 2016364976A AU 2016364976 A AU2016364976 A AU 2016364976A AU 2016364976 B2 AU2016364976 B2 AU 2016364976B2
Authority
AU
Australia
Prior art keywords
compound
dispersion
disease
solid dispersion
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016364976A
Other languages
English (en)
Other versions
AU2016364976A1 (en
Inventor
Craig Anthony DUNBAR
Ahmad Hashash
Vasu SETHURAMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclerion Therapeutics Inc
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of AU2016364976A1 publication Critical patent/AU2016364976A1/en
Assigned to CYCLERION THERAPEUTICS, INC. reassignment CYCLERION THERAPEUTICS, INC. Request for Assignment Assignors: IRONWOOD PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2016364976B2 publication Critical patent/AU2016364976B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016364976A 2015-11-30 2016-11-22 Solid dispersions comprising a sGC stimulator Active AU2016364976B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562260910P 2015-11-30 2015-11-30
US62/260,910 2015-11-30
US201662359440P 2016-07-07 2016-07-07
US62/359,440 2016-07-07
PCT/US2016/063312 WO2017095697A1 (en) 2015-11-30 2016-11-22 Solid dispersions comprising a sgc stimulator

Publications (2)

Publication Number Publication Date
AU2016364976A1 AU2016364976A1 (en) 2018-06-14
AU2016364976B2 true AU2016364976B2 (en) 2022-08-25

Family

ID=57590822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016364976A Active AU2016364976B2 (en) 2015-11-30 2016-11-22 Solid dispersions comprising a sGC stimulator

Country Status (12)

Country Link
US (4) US20190269619A1 (enExample)
EP (1) EP3383372B1 (enExample)
JP (3) JP6952707B2 (enExample)
KR (1) KR102841419B1 (enExample)
CN (4) CN108883071A (enExample)
AU (1) AU2016364976B2 (enExample)
BR (1) BR112018011154B1 (enExample)
CA (1) CA3006746C (enExample)
EA (1) EA201891315A1 (enExample)
IL (2) IL259493B (enExample)
MX (3) MX389961B (enExample)
WO (1) WO2017095697A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7098214B2 (ja) * 2016-02-01 2022-07-11 サイクレリオン・セラピューティクス，インコーポレーテッド 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
CA3029375A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Novel processes for preparation of soluble guanylate cyclase stimulators
SG10202100168XA (en) * 2016-07-07 2021-02-25 Cyclerion Therapeutics Inc Novel processes for preparation of soluble guanylate cyclase stimulators
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
EP3737679B1 (en) * 2018-01-10 2023-09-06 Cyclerion Therapeutics, Inc. Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
EP3829644A4 (en) * 2018-07-30 2022-05-04 Ricoh Company, Ltd. PROCESS FOR MANUFACTURING PARTICLES AND PARTICLE AND MEDICATION MANUFACTURED BY THE PROCESS
CN118319863A (zh) * 2019-09-23 2024-07-12 生态有限公司 治疗制剂及其用途
CN115175683A (zh) 2019-10-29 2022-10-11 赛克里翁治疗有限公司 用sGC刺激剂治疗糖尿病性肾病
KR20230121867A (ko) * 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 무정형 고체 분산체
WO2023009710A1 (en) 2021-07-28 2023-02-02 Cyclerion Therapeutics, Inc. Treatment of hfpef in post-menopausal women with an sgc stimulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144100A2 (en) * 2013-03-15 2014-09-18 Takashi Nakai Sgc stimulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
DE60039379D1 (de) * 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
WO2014047111A1 (en) * 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144100A2 (en) * 2013-03-15 2014-09-18 Takashi Nakai Sgc stimulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROADHEAD J. et al., "The Spray Drying of Pharmaceuticals", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (1992), vol. 18, no. 11/12, pages 1169 - 1206 *
FRIESEN D. T. et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", MOLECULAR PHARMACEUTICS, (2008), vol. 5, no. 6, pages 1003 - 1019 *
LEUNER C. et al., "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., (2000), vol. 50, no. 1, pages 47 - 60 *
TIWARI R. et al., "Solid dispersions: An overview to modify bioavailability of poorly water soluble drugs", INTERNATIONAL JOURNAL OF PHARMTECH RESEARCH, SHPINX KNOWLEDGE HOUSE, (2009), vol. 1, no. 4, pages 1338 - 1349 *

Also Published As

Publication number Publication date
CN108883071A (zh) 2018-11-23
IL290338B1 (en) 2023-01-01
US20190269619A1 (en) 2019-09-05
CN116942616A (zh) 2023-10-27
IL290338B2 (en) 2023-05-01
US20250017862A1 (en) 2025-01-16
MX389961B (es) 2025-03-20
EP3383372A1 (en) 2018-10-10
IL259493B (en) 2022-03-01
CA3006746A1 (en) 2017-06-08
MX2022001656A (es) 2022-03-11
AU2016364976A1 (en) 2018-06-14
US20250255821A1 (en) 2025-08-14
EP3383372B1 (en) 2023-11-01
JP6952707B2 (ja) 2021-10-20
JP2022000464A (ja) 2022-01-04
US20240293324A1 (en) 2024-09-05
EA201891315A1 (ru) 2018-12-28
WO2017095697A1 (en) 2017-06-08
KR102841419B1 (ko) 2025-08-01
CN116637077A (zh) 2023-08-25
BR112018011154A2 (pt) 2018-11-21
CN116637076A (zh) 2023-08-25
JP2023100851A (ja) 2023-07-19
MX2022001655A (es) 2022-03-11
JP2019501216A (ja) 2019-01-17
BR112018011154B1 (pt) 2023-09-26
IL290338A (en) 2022-04-01
CA3006746C (en) 2024-01-30
JP7277534B2 (ja) 2023-05-19
JP7641320B2 (ja) 2025-03-06
KR20180086497A (ko) 2018-07-31
IL259493A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
US20250255821A1 (en) Solid dispersions comprising a sgc stimulator
CN111818918B (zh) 用于治疗囊性纤维化的药物组合物
TWI719349B (zh) Ｃｆｔｒ調節劑之結晶形式及組合物
JP5017115B2 (ja) ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物
US20210228489A1 (en) Compositions for treating cystic fibrosis
US10590089B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2020242935A1 (en) Methods of treatment for cystic fibrosis
HK1261747B (en) Solid dispersions comprising a sgc stimulator
HK1261747A1 (en) Solid dispersions comprising a sgc stimulator
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
EA043018B1 (ru) Твердые дисперсии, содержащие стимулятор sgc, для применения в качестве лекарственного средства

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYCLERION THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): IRONWOOD PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)